PY for all patients on chronic dialysis and 9.6/1000 PY for dialysis patients aged 65 yr or younger. Among RT recipients, graft loss (AHR, 2.97; 95% CI, 2.19 to 4.02), allograft rejection, and cadaveric donation were independently associated with psychosis, which was associated with an increased risk of both death (AHR, 2.09; 95% CI, 1.71 to 2.56; P Ͻ 0.001) and graft loss (AHR, 1.79; 95% CI, 1.15 to 2.78; P ϭ 0.01). Graft loss due to noncompliance was significantly more common after psychosis (9.0% versus 3.7% in patients not hospitalized for psychosis; P Ͻ 0.001). The incidence of hospitalized psychosis was not substantially higher after RT compared with chronic dialysis patients. Psychoses were independently associated with increased risk of death and graft loss after renal transplantation, possibly mediated through medical non-adherence.
Psychoses are among the most frequent indications for hospitalization in the United States (1) . Successful renal transplantation has been reported in patients with underlying psychiatric disorders before transplant (2) . Psychiatric disorders are more common in chronic dialysis patients than in the general population (3) and have been shown to adversely impact survival in hemodialysis patients (4) . However, psychosis occurring after renal transplantation has been infrequently described (5) (6) (7) (8) (9) . There are several potential reasons why renal transplantation may predispose patients to an increased risk of psychosis: use of high-dose corticosteroids, a known risk factor for psychosis (8) ; chronic illness-associated affective disorders; metabolic factors associated with renal transplantation; and other immunosuppressive medications used in transplantation, such as calcineurin inhibitors, which have known neuropsychologic side effects (10) . Conversely, it is recommended that all candidates for renal transplantation be screened for mental health disorders, and significant mental health problems are considered a contraindication to renal transplantation (11) , given concerns over medical non-adherence. It is therefore also possible that psychoses might be less common after renal transplantation than among comparable patients undergoing chronic dialysis. Given the profound trauma associated with hospitalized psychosis on both patients and families, having a better understanding of its incidence and risk factors would allow for directed efforts toward potential preventive efforts. Therefore, using national data from the United States Renal Data System (USRDS) report, we sought to determine the rate of hospitalizations for a primary and secondary diagnosis of psychoses in renal transplant recipients in comparison with patients with end-stage renal disease on chronic dialysis.
Materials and Methods

Patients
Two patient cohorts were used for analysis. First, a cohort of all solitary renal transplant recipients from July 1, 1994, to June 30, 1998, were studied for analysis of transplant-specific risk factors and mortality. Second, a cohort of patients who started dialysis from April 1, 1995, to June 29, 1999, were studied for comparison of rates of hospitalized psychosis between renal transplant recipients and comparable chronic dialysis patients.
Renal Transplant Patient Population
This study used data from the United States Renal Data System (USRDS), using standard analysis files (SAF) that include data on renal transplant recipients from July 1994 to May 2000. The USRDS, indirectly mandated by federal law, incorporates baseline and follow-up demographic and clinical data on all patients receiving end-stage renal disease (ESRD) therapy in the United States. ESRD therapy includes hemodialysis, peritoneal dialysis, and renal transplantation. The variables included in the USRDS standard analysis files (SAF), as well as data collection methods and validation studies, are listed on the USRDS web site (http://www.usrds.org), under "Researcher's Guide to the USRDS Database," Section E, "Contents of all the SAF's" and published in the USRDS. The demographics of the renal transplant population have been previously described (2001 USRDS report). SAF.TXUNOS was used as the primary data set and was merged with variables from SAF.HOSP for hospitalization data using unique patient identifiers and SAF.PATIENTS for dates and causes of death as well as causes of renal disease, as previously reported. Patient characteristics and treatment factors were those at the date of transplant. Recipients of organs other than kidneys were excluded.
Patients on Chronic Dialysis
For purposes of comparison with patients on chronic dialysis patients, this study also used a population of patients who started dialysis from April 1, 1995, to June 29, 1999 (after the date the Center for Medicare and Medicaid Studies Form 2728 expanded to include comorbidity data with evidence of Medicare as primary payer). Files were merged as specified above.
Outcome Definition
The definition of hospitalized cases of psychoses was based on the primary discharge diagnosis that included the International Classification of Diseases-9th Modification Diagnosis Codes (ICD-9) for psychoses, 290.x-299.x. The first hospitalization for psychoses after the first renal transplant for a given individual occurring on or after July 1, 1994, and before July 1, 1998, with follow-up time censored at 3 yr was counted in analysis. Hospitalizations were chosen because they were more accessible in the database and less subject to interpretation than outpatient cases of psychoses. Hospitalization data for transplant recipients may be unreliable after the patient has survived Ն 3 yr posttransplant, when hospitalization reporting to Medicare for patients 65 yr or younger is no longer required. All hospitalizations with a primary discharge diagnosis for psychoses were extracted from SAF.HOSP and merged with the transplant file, and hospitalizations outside the range of the study period were excluded. Hospitalizations for psychoses occurring at any time after renal transplant, including after graft failure, were counted in analysis. However, for analysis of the entire cohort of renal transplant recipients from 1994 to 1998, only the first hospitalization for psychosis during the study period was assessed in risk factor analysis. For analysis comparing rates of psychosis between transplant patients and dialysis patients, all hospitalizations were assessed in analysis to avoid potential bias. The date and cause of patient death was obtained from variables in the file SAF.PATIENTS. The date and cause of graft loss were obtained from the file SAF.TXFUUNOS.
Variables
The independent associations between patient factors and hospitalizations for psychoses were examined using multivariate analysis with stepwise Cox regression, including recipient and donor age, recipient race, gender, weight, pretransplant dialysis (yes/no), duration of dialysis before transplantation, total follow-up time, repeat transplant, dialysis in the first week after transplant (delayed graft function, yes/no), rejection (either treatment or diagnosis) occurring at any time in the study period, induction antibody therapy, maintenance immunosuppressive medications at time of discharge after transplant surgery, graft loss, and cause of ESRD (diabetes, systemic lupus erythematosus [SLE]). SLE was chosen because of the additional corticosteroid use and documented risk of SLE cerebritis in these patients. Episodes of rejection were not restricted to those occurring in the first year, in contrast to studies of allograft function, because there is no evidence that late (versus early) rejection has a different impact on psychoses. However, only episodes of psychosis occurring after the approximate date of rejection were used in analysis of this variable. The total cumulative dose of prednisone was not available in the USRDS. Maintenance immunosuppressive medication use at the time of discharge after transplantation was also analyzed as a preexisting covariate. Information on use of medications (other than immunosuppressive medications), alcohol, tobacco, or illicit drugs was not available.
Survival Times
For time to hospitalized psychosis, survival time was defined as the time from first renal transplant until hospitalization for psychosis, with patients censored at death, loss to follow-up, 3 yr after the date of renal transplant, or the end of the study. Because the most recent date of hospitalization was December 31, 1999, this was considered the end of the study period for this survival time. For calculation of survival after hospitalization for psychosis, survival time was calculated as the time from the admission date until death, censored for loss to follow-up, 3 yr after the date of renal transplantation, or the end of the study period (in this case, April 9, 2000) . The patient survival probabilities were estimated by using the Kaplan Meier method. Graft survival time (censored for patient death) was calculated as the time from the date of transplant until the date of graft loss, censored for death, loss to follow-up, 3 yr after the date of renal transplantation, or the end of the study period (also considered April 9, 2000) . For analysis of patients on chronic dialysis, time to hospitalized psychosis was calculated from the date of dialysis until hospitalization for psychosis, censored for death, loss to follow-up, or the end of the study period (same dates as above). Survival time was calculated as the time from first dialysis until death, censored for loss to follow-up or the end of the study period.
Statistical Analysis
All analyses were performed using SPSS 9.0 TM (SPSS, Inc., Chicago, IL). Files were merged and converted to SPSS files using DBMS/Copy (Conceptual Software, Houston, TX). Univariate analysis was performed with 2 testing for categorical variables (using the Fisher exact test for violations of Cochran assumptions) and two-sided t test for continuous variables (using the Mann-Whitney U test for variables that did not have a Gaussian distribution). Variables with P Ͻ 0.10 in univariate analysis for a relationship with development of hospitalization for psychoses were entered into multivariate analysis as covariates. Life tables analysis was used to calculate 1-yr incidences of psychoses by year of transplantation. Log-log plots were used to assess the proportionality of hazards over time. Kaplan-Meier analysis was used to construct survival plots of time to hospitalized psychoses after renal transplantation. Stepwise Cox regression (forward stepwise likelihood ratio method) was used to model factors associated with time to hospitalized psychoses, controlling for covariates listed above. For the cohort of wait-listed patients, renal transplantation was modeled as a time-dependent variable in Cox nonpro-portional hazards regression analysis, with all times after transplantation coded as 1, otherwise as 0. For the cohort of all renal transplant recipients, graft loss was similarly modeled as a timedependent variable. The association between hospitalized for psychoses and mortality was also modeled using Cox nonproportional hazards regression, with hospitalized psychoses assessed as a timedependent variable. Model selection was tested using random samples (70%) of the study population and assessing the validity of these models in the remaining 30% of the study population. Ultimate decisions on the final model were made on the basis of the combination of the best statistical fit as well as the clinical relevance of variables remaining in the model (12) .
Results
There were 42,096 solitary renal transplant recipients in the United States Renal Data System transplanted from July 1, 1994, to June 30, 1998, of whom 39,628 (94.1%) had data complete enough to calculate survival times. Mean follow-up was 1.89 Ϯ 1.15 yr (median, 1.91 yr). Of these, 420 recipients were hospitalized with a primary discharge diagnosis of psychoses, and 199 were hospitalized with a secondary diagnosis of psychosis, of whom 54 also had a primary discharge diagnosis of psychoses. This resulted in a total of 565 patients with either a primary or secondary discharge diagnosis of psychoses, with an incidence density of 7.5/1000 person-years (PY). Of patients hospitalized for psychoses, 75% were hospitalized once, 14% twice, 5% three times, 3% four times, and 3.6% more than four times (the maximum number of hospitalizations for psychoses during the study period was nine).
In analysis of renal transplant recipients (Table 1) , cadaver kidney (versus living donor), allograft rejection, graft loss, delayed graft function, and elevated serum creatinine level (at most recent follow-up date) were significantly different between recipients hospitalized for psychoses versus all other recipients. Several maintenance immunosuppressive medica- tions were also significant in unadjusted analysis; azathioprine and cyclosporine were associated with reduced risk of psychosis, while tacrolimus was associated with increased risk of psychosis. The time to hospitalization for a primary diagnosis of psychoses is shown in Figure 1 , and for a secondary diagnosis of psychoses is shown in Figure 2 . In both cases, there was a slight early peak in risk during the first few months after transplant (more pronounced in patients with a secondary diagnosis); risk was otherwise constant over time. Hospitalizations with a secondary diagnosis of psychoses were less frequent (Table 2) , and associations were not substantially different. No immunosuppressive medications (specifically mycophenolate) were significant even in unadjusted analysis.
In Cox regression analysis with time to hospitalization for psychoses after transplantation as the outcome variable, significant associations were found only with graft loss (as a timedependent variable), allograft rejection, and cadaver kidney (Table 1 ). There were no significant interactions among covariates, specifically no interactions among maintenance or induction medications, graft loss, or serum creatinine level. Tables 2 and 3 show subcategories of primary and secondary diagnoses of hospitalized psychoses for patients after renal transplantation (Table 2 ) and for patients on chronic dialysis (Table 3) . Among renal transplant recipients (Table 2) , one third (37%) of the primary psychoses diagnoses were subcategorized as psychotic depression, whereas drug-induced delirium was the leading subcategory for secondary diagnoses of psychoses. Differences between transplant recipients and dialysis patients were striking. While psychosis was more common as a primary than as a secondary diagnosis after renal transplantation, about 85% of all hospitalizations for psychoses were coded as secondary diagnoses in dialysis patients. Furthermore, acute delirium (comprised of various subcategories) was the leading diagnosis for both primary and secondary diagnosis in chronic dialysis patients, while psychotic depression was much less common than after transplantation. Schizophrenia was rare among transplant recipients, but was much more common among dialysis patients, as was senile or presenile psychosis.
Among renal transplant recipients, mortality after a primary diagnosis for hospitalized psychoses was nearly 50% at three years after hospitalization (Figure 3) , compared with 9.3% after 3 yr after the date of transplant for the entire cohort. Mortality after primary hospitalized psychosis was similar whether the subcategory was drug-related or not (Figure 4) . In Cox nonproportional hazards regression, mortality was significantly increased after primary hospitalization for psychoses compared with recipients who were not hospitalized for psychosis (adjusted hazard ratio [AHR], 2.09; 95% CI, 1.71 to 2.56; P Ͻ 0.001). The leading cause of death was unknown in 24% of patients with psychoses who died, followed by cardiac arrest with unknown cause (10.4%), sepsis (9.4%), stroke (8.3%), cardiomyopathy (5.2%), malignancy (4.2%), and 2.2% each for acute myocardial infarction, atherosclerotic heart disease, and cardiac arrhythmia. Only one death due to suicide was reported. Mortality did not differ significantly by subcategory of psychosis as specified in Table 1 . Mortality after a secondary diagnosis of psychosis was even higher, at nearly 70% at 3 yr (not shown). As a time-dependent covariate, hospitalization for a secondary diagnosis of psychosis was also independently associated with increased mortality (AHR, 3.99; 95% CI, 3.04 to 5.24; P Ͻ 0.001).
Among renal transplant recipients, at 3 yr, death-censored graft loss occurred in 25.5% of patients eventually hospitalized for psychosis versus 6.4% of patients not hospitalized for Time to hospitalized psychoses (as a secondary diagnosis) after renal transplantation, all US solitary renal transplant recipients, July 1, 1994, to June 30, 1998. As shown, there was a slight early peak in risk during the first few months after transplantation; otherwise, risk was constant over time.
psychosis (P Ͻ 0.001 by log rank test). Causes of graft loss were similar between patients hospitalized for psychosis and those who were not except for noncompliance. As a cause of graft loss, noncompliance occurred in 9.0% of renal transplant recipients hospitalized for psychosis versus 3.7% of renal a Totals include only the FIRST hospitalization for psychosis after renal transplantation during the study period. Twenty four patients had both a first and secondary diagnosis of psychosis. a Totals include ALL hospitalizations during the study period, allowing multiple hospitalizations per patient in order to avoid bias toward dialysis patients (if using only the first hospitalization) or toward transplant patients (if using only the last hospitalization). Mortality after hospitalized psychoses (as a primary diagnosis). As shown, mortality was nearly 50% at 3 yr after hospitalization. As a time-dependent variable in Cox nonproportional hazards regression, hospitalized psychoses were independently associated with increased mortality (adjusted hazard ratio, 2.09; 95% CI, 1.71 to 2.56; P Ͻ 0.001). Mortality did not differ significantly depending on the classification of psychoses (Table 1 ). transplant patients not hospitalized for psychosis (P Ͻ 0.001 by 2 test). In Cox nonproportional hazards regression analysis, hospitalized psychosis was independently associated with graft loss (AHR, 1.79; 95% CI, 1.15 to 2.78; P ϭ 0.01). Among renal transplant recipients with graft loss, hospitalized psychosis was independently associated with graft loss due to noncompliance in Cox nonproportional hazards regression analysis (AHR, 2.51; 95% CI, 1.28 to 4.91; P ϭ 0.007). Results of analysis of psychosis as a secondary diagnosis were similar.
Tables 4 shows characteristics and risk factors for hospitalized psychoses for chronic dialysis patients. Because most dialysis patients had psychoses coded as a secondary diagnosis, and because the distribution of subcategories was not different, separate analyses of primary and secondary diagnoses were not performed. The incidence density of psychoses was 7.2/1000 PY among chronic dialysis patients. The incidence density of psychoses among patients younger than 65 yr was 9.6/1000 PY. The incidence density of psychoses after renal transplantation in this cohort was 3.0/1000 PY. However, after adjustment for all variables shown in Table 4 , this difference was not statistically significant. Illicit drug use and smoking had the strongest associations with psychoses. Also, despite the limitation of the study population to those who were primarily Medicare-eligible, hospitalized psychoses were significantly more common among patients who were younger than age 65 yr. As a time-dependent variable, renal transplantation was not significantly associated with hospitalized psychoses in this elderly cohort. Cumulative mortality after hospitalized psychoses was 53% at 1 yr, 73% at 2 yr, and 84% at 3 yr. Hospitalized psychoses were also independently associated with increased risk of mortality in chronic dialysis patients as a time-dependent variable (AHR for mortality, 1.87; 95% CI, 1.77 to 1.98; P Ͻ 0.001, in Cox regression analysis adjusted for all factors shown in Table 5 ).
Discussion
The present study indicates that hospitalized psychosis, whether as a primary or secondary diagnosis, was associated with dismal survival among both renal transplant recipients and chronic dialysis patients. Among renal transplant recipients, differences in mortality according to subcategory of diagnosis, particularly subcategories that might be more transient, such as drug-related psychosis, were not statistically significant. Cause of death data (limited by a large number of missing and unknown causes) did not indicate a primary psychiatric cause in most deaths, particularly not suicide. While statistical comparison must be interpreted with caution due to the lack of comparability between groups (renal transplantation was an unusual event in the chronic elderly dialysis cohort selected), it does not appear that psychoses are more common after renal transplantation than among chronic dialysis patients. Models adjusted for age, race, gender, diabetes, systemic lupus erythematosus, comorbid conditions from CMV a As a time-dependent variable. From 2728, and year of first ESRD treatment. AHR, adjusted hazard ratio for hospitalized psychosis in Cox Regression analysis. In contrast to Table 1 , this model analyzed all hospitalizations for psychoses to avoid potential bias in selecting either the first hospitalization (which would be weighted toward dialysis patients) or the last hospitalization (which would be weighted toward transplant recipients).
b The model including the variable for HIV-positive was limited to 32,763 patients due to missing values for this variable, and it excluded patients may not be representative of the entire population.
Reports have indicated that mental health-related disorders are common in patients with chronic kidney disease (3) but are substantially undertreated (13) and lead to increased risk of death (4) . Due to recommendations for screening for mental health-related disorders before transplant, it might be expected that psychosis would be significantly less common after renal transplantation than among dialysis patients. However, almost all renal transplant recipients were on maintenance corticosteroids, a known contributor to drug-related psychosis, and virtually all recipients received high doses at the time of transplantation. However, it would appear that factors related to pretransplant screening, resulting in a highly selected population, were more important in the relative incidence of psychoses after transplantation (in comparison with the chronic dialysis population) than medication effects.
Although the USRDS database does not track cumulative doses of corticosteroids, allograft rejection was one of the leading risk factors for hospitalized psychoses. It is possible that allograft rejection and receipt of a cadaveric kidney were surrogate markers for higher doses of corticosteroids. Elevated serum creatinine was also associated with psychosis in unadjusted, but not adjusted analysis, suggesting that renal insufficiency may be associated with the risk of psychoses. Graft loss was the strongest risk factor for psychosis in the present analysis, however. The exact reasons for the high risk of graft loss are difficult to define from the database; such patients could have received higher doses of corticosteroids, or had metabolic, infectious, or autoimmune complications, interventions, or stressors that would increase susceptibility to psychotic reactions. Renal insufficiency could result in higher levels of certain medications (particularly calcineurin inhibitors, because corticosteroids are not generally influenced by renal function) that could cause psychotic symptoms (14) . We could not implicate any specific immunosuppressive agents as independently associated with hospitalized psychosis in adjusted analysis. The differences in the rates of psychoses according to immunosuppression in Table 1 (none of which were significant in multivariate analysis) may be due to confounding by the two factors that were significant in analysis, namely allograft rejection and graft loss. In particular, the univariate association of psychosis with tacrolimus may be due to confounding by indication, because in the time frame of this analysis tacrolimus was used disproportionately in patients who were "high-risk."
Commonly used antipsychotic agents such as haloperidol have no significant interactions with either corticosteroids or calcineurin inhibitors, and their dosage is not affected by renal function. However, it is also possible that renal insufficiency may have led to undertreatment of patients with psychosis, as noted previously for patients with depression (15) , and as has been demonstrated with cardiovascular disease (16) .
One important possible mechanism for both mortality and graft loss after hospitalized psychosis is non-adherence (a term preferred to noncompliance [16] ) and denial of illness (17) . Alexithymia (an inability to process or communicate emotions) has been described in a high proportion of renal transplant recipients (18) , which has been associated with non-adherence.
Although non-adherence is not reliably listed as a cause of death after renal transplantation, non-adherence as a specified cause of graft loss was significantly more common in patients hospitalized for psychosis than in patients not hospitalized for psychosis, and specific causes of graft loss have been utilized in previous studies (18) . The increased risk of mortality among patients hospitalized for psychosis was independent of graft loss, suggesting a role for other factors, possibly including non-adherence with non-immunosuppressive medications as well. non-adherence has been well documented in patients with psychotic depression (19, 20) and psychosis (21) , which is important to recognize because behavioral therapy and psychiatric intervention have been helpful (22) . The associations between depressive disorders and ESRD, renal dialysis, and both renal and other organ transplantation have been well described (16, 23) . However, the primary healthcare providers for transplant patients (transplant surgeons and nephrologists) do not have formal training in the assessment and provision of mental health services; as a consequence, they are generally uncomfortable addressing medical noncompliance in general, and psychiatric issues in particular (24) . Further clinical trials should test these questions prospectively, and there should be consideration of professional development in the mental health arena among healthcare providers for renal transplant recipients.
This study has several limitations. First, we were unable to verify DSM-IV criteria for diagnosis. Because DSM coding includes psychotic depression as a subcategory of psychoses, it is possible that affective disorders could have been included in analysis. Second, we could only study hospitalized patients. However, most episodes of acute psychoses are managed with hospitalization (25) . Third, our study was limited to hospitalizations with a primary and secondary discharge diagnosis of psychosis, and therefore possibly underestimates total cases of hospitalized psychoses. Our analysis of the entire cohort of chronic dialysis patients was limited to patients who had evidence of Medicare as their primary payer; therefore, underascertainment is possible. The substantially lower rate of hospitalized psychoses after renal transplantation in the cohort of chronic dialysis patients (3.0/1000 PY in comparison with 7.5/1000 PY in the cohort of all renal transplant recipients) likely reflects substantial selection bias, because renal transplantation was much less common among elderly dialysis patients. Furthermore, hospitalized psychoses were significantly more common in younger chronic dialysis patients, at least in this cohort. Although universal screening of transplant candidates for mental health disorders is recommended, we were unable to verify whether this occurred or the methods (such as the Beck Depression Inventory [26] ) and personnel used to conduct such screening, which can affect outcomes after transplant. Another possible cause of underestimation of the risk of psychosis is that patients with mental disorders, and particularly prior psychoses, tend to be excluded from eligibility for transplant, which should therefore select for a cohort who would be less susceptible to psychosis. We were unable to directly measure adherence with medications and other prescribed treatments during the course of the study. We were also unable to verify diagnoses of non-adherence as coded in the database.
In summary, hospitalized psychoses occurring after renal transplantation were apparently not more common than among chronic dialysis patients. However, hospitalized psychoses were associated with a substantially increased risk of death and graft loss after renal transplantation, which may be at least partially mediated by undertreatment by medical providers or by patient non-adherence.
